TY - JOUR
T1 - Assessment and Monitoring Challenges Among Patients With Moderate-to-Severe Atopic Dermatitis Across Fitzpatrick Skin Types
T2 - A Photographic Review and Case Series
AU - Aoki, Valeria
AU - Oliveira, Marilia
AU - Wegzyn, Colleen
AU - Desai, Seemal R.
AU - Jewell, Susan
AU - Ladizinski, Barry
AU - Simpson, Eric L.
N1 - Funding Information:
This study was financially supported by AbbVie.
Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Atopic dermatitis (AD) is a common, chronic, inflammatory skin condition that affects people of all ages, races, and ethnicities. The condition is heterogeneous in both clinical presentation (phenotype) and underlying pathobiology (endotype). Atopic dermatitis diagnosis, assessment, and monitoring rely on clinical evaluation because there are no definitive biomarkers for AD. This review addresses variation in the clinical presentation of AD across the spectrum of Fitzpatrick skin types, with an emphasis on clinical evaluation challenges in patients with skin of color. We present photographs from phase 3 clinical trials that evaluated the safety and efficacy of upadacitinib among patients with moderate-to-severe AD and demonstrate the challenges in evaluating the clinical signs of AD (erythema and excoriation in patients with dark skin types and lichenification in those with light skin types) by illustrating the changes in clinical signs and symptoms that can be achieved with targeted systemic therapies.
AB - Atopic dermatitis (AD) is a common, chronic, inflammatory skin condition that affects people of all ages, races, and ethnicities. The condition is heterogeneous in both clinical presentation (phenotype) and underlying pathobiology (endotype). Atopic dermatitis diagnosis, assessment, and monitoring rely on clinical evaluation because there are no definitive biomarkers for AD. This review addresses variation in the clinical presentation of AD across the spectrum of Fitzpatrick skin types, with an emphasis on clinical evaluation challenges in patients with skin of color. We present photographs from phase 3 clinical trials that evaluated the safety and efficacy of upadacitinib among patients with moderate-to-severe AD and demonstrate the challenges in evaluating the clinical signs of AD (erythema and excoriation in patients with dark skin types and lichenification in those with light skin types) by illustrating the changes in clinical signs and symptoms that can be achieved with targeted systemic therapies.
UR - http://www.scopus.com/inward/record.url?scp=85142403777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142403777&partnerID=8YFLogxK
U2 - 10.1097/DER.0000000000000864
DO - 10.1097/DER.0000000000000864
M3 - Review article
C2 - 35318974
AN - SCOPUS:85142403777
SN - 1710-3568
VL - 33
SP - S24-S36
JO - Dermatitis : contact, atopic, occupational, drug
JF - Dermatitis : contact, atopic, occupational, drug
IS - 6
ER -